
Opinion|Videos|May 7, 2024
Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMO
Author(s)Marion R. Munk, MD, PhD
Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.
Advertisement
Episodes in this series
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Retina World Congress 2026: Identifying real-world durability gaps in wet AMD treatment
2
Retina World Congress 2026: Diagnosing macular telangiectasia in a field of mimickers
3
Retina World Congress 2026: Rethinking macular hole surgery without gas tamponade
4
Retina World Congress 2026: The case for earlier surgical intervention in diabetic macular edema
5






















